

# Ann-Mari Svennerholm

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10704342/publications.pdf>

Version: 2024-02-01

205  
papers

10,198  
citations

30070

54  
h-index

46799

89  
g-index

210  
all docs

210  
docs citations

210  
times ranked

5848  
citing authors

#	ARTICLE	IF	CITATIONS
1	Enterotoxigenic <i>Escherichia coli</i> in Developing Countries: Epidemiology, Microbiology, Clinical Features, Treatment, and Prevention. <i>Clinical Microbiology Reviews</i> , 2005, 18, 465-483.	13.6	804
2	Identification of <i>Escherichia coli</i> heat-labile enterotoxin by means of a ganglioside immunosorbent assay (GM1-ELISA) procedure. <i>Current Microbiology</i> , 1978, 1, 19-23.	2.2	352
3	FIELD TRIAL OF ORAL CHOLERA VACCINES IN BANGLADESH. <i>Lancet, The</i> , 1986, 328, 124-127.	13.7	345
4	Protection against Cholera in Breast-Fed Children by Antibodies in Breast Milk. <i>New England Journal of Medicine</i> , 1983, 308, 1389-1392.	27.0	334
5	<i>Helicobacter pylori</i> Specific CD4 <sup>+</sup> CD25 <sup>high</sup> Regulatory T Cells Suppress Memory T-Cell Responses to <i>H. pylori</i> in Infected Individuals. <i>Infection and Immunity</i> , 2003, 71, 1755-1762.	2.2	288
6	Mucosal <i>FOXP3</i> -Expressing CD4 <sup>+</sup> CD25 <sup>high</sup> Regulatory T Cells in <i>Helicobacter pylori</i> -Infected Patients. <i>Infection and Immunity</i> , 2005, 73, 523-531.	2.2	246
7	Cholera Due to Altered El Tor Strains of <i>Vibrio cholerae</i> O1 in Bangladesh. <i>Journal of Clinical Microbiology</i> , 2006, 44, 4211-4213.	3.9	222
8	Identification of enterotoxigenic <i>Escherichia coli</i> (ETEC) clades with long-term global distribution. <i>Nature Genetics</i> , 2014, 46, 1321-1326.	21.4	192
9	Disease Burden Due to Enterotoxigenic <i>Escherichia coli</i> in the First 2 Years of Life in an Urban Community in Bangladesh. <i>Infection and Immunity</i> , 2007, 75, 3961-3968.	2.2	180
10	Prevalence of Toxin Types and Colonization Factors in Enterotoxigenic <i>Escherichia coli</i> Isolated during a 2-Year Period from Diarrheal Patients in Bangladesh. <i>Journal of Clinical Microbiology</i> , 2000, 38, 27-31.	3.9	173
11	Mucosal Immunity: Implications for Vaccine Development. <i>Immunobiology</i> , 1992, 184, 157-179.	1.9	168
12	Development of improved cholera vaccine based on subunit toxoid. <i>Nature</i> , 1977, 269, 602-604.	27.8	134
13	Vaccines against mucosal infections. <i>Current Opinion in Immunology</i> , 2012, 24, 343-353.	5.5	132
14	Mechanisms of Disease and Immunity in Cholera: A Review. <i>Journal of Infectious Diseases</i> , 1977, 136, S105-S112.	4.0	130
15	Enterotoxigenic <i>Escherichia coli</i> and <i>Vibrio cholerae</i> Diarrhea, Bangladesh, 2004. <i>Emerging Infectious Diseases</i> , 2005, 11, 1104-1107.	4.3	123
16	Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic <i>Escherichia coli</i> (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study. <i>Vaccine</i> , 2014, 32, 7077-7084.	3.8	117
17	Development of oral vaccines against enterotoxinogenic <i>Escherichia coli</i> diarrhoea. <i>Vaccine</i> , 1989, 7, 196-198.	3.8	114
18	Identification of a mannose-binding pilus on <i>Vibrio cholerae</i> El Tor. <i>Microbial Pathogenesis</i> , 1991, 11, 433-441.	2.9	114

#	ARTICLE	IF	CITATIONS
19	Vaccines against enterotoxigenic <i>Escherichia coli</i> . Expert Review of Vaccines, 2008, 7, 795-804.	4.4	107
20	Safety and immunogenicity of an oral recombinant cholera B subunit "whole cell vaccine in Swedish volunteers. Vaccine, 1992, 10, 130-132.	3.8	106
21	Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. Vaccine, 2007, 25, 4392-4400.	3.8	102
22	Shifting Prevalence of Major Diarrheal Pathogens in Patients Seeking Hospital Care during Floods in 1998, 2004, and 2007 in Dhaka, Bangladesh. American Journal of Tropical Medicine and Hygiene, 2008, 79, 708-714.	1.4	101
23	Oral Immunization with a <i>Salmonella enterica</i> Serovar Typhi Vaccine Induces Specific Circulating Mucosa-Homing CD4 <sup>+</sup> and CD8 <sup>+</sup> T Cells in Humans. Infection and Immunity, 2002, 70, 5622-5627.	2.2	97
24	Intestinal Immune Responses to an Inactivated Oral Enterotoxigenic <i>Escherichia coli</i> Vaccine and Associated Immunoglobulin A Responses in Blood. Infection and Immunity, 1998, 66, 3311-3316.	2.2	97
25	Recent progress toward an enterotoxigenic <i>Escherichia coli</i> vaccine. Expert Review of Vaccines, 2012, 11, 495-507.	4.4	94
26	Safety and immunogenicity of an oral inactivated enterotoxigenic <i>Escherichia coli</i> vaccine. Vaccine, 1998, 16, 255-260.	3.8	93
27	Phenotypic Profiles of Enterotoxigenic <i>Escherichia coli</i> Associated with Early Childhood Diarrhea in Rural Egypt. Journal of Clinical Microbiology, 2004, 42, 5588-5595.	3.9	87
28	Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine, 2013, 31, 452-460.	3.8	86
29	Development of Multiplex PCR Assays for Detection of Enterotoxigenic <i>Escherichia coli</i> Colonization Factors and Toxins. Journal of Clinical Microbiology, 2009, 47, 1218-1220.	3.9	85
30	Safety, Immunogenicity, and Protective Efficacy of the Whole-Cell/Recombinant B Subunit (WC/rBS) Oral Cholera Vaccine Against Travelers' Diarrhea. Journal of Travel Medicine, 1995, 2, 22-27.	3.0	83
31	<i>Helicobacter pylori</i> -Specific CD4 <sup>+</sup> T Cells Home to and Accumulate in the Human <i>Helicobacter pylori</i> -Infected Gastric Mucosa. Infection and Immunity, 2005, 73, 5612-5619.	2.2	83
32	Safety and immunogenicity of the oral, inactivated, enterotoxigenic <i>Escherichia coli</i> vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial. Lancet Infectious Diseases, The, 2020, 20, 208-219.	9.1	81
33	Intestinal antibody response after oral immunization with a prototype cholera B subunit " colonization factor antigen enterotoxigenic <i>Escherichia coli</i> vaccine. Vaccine, 1993, 11, 929-934.	3.8	78
34	High Disease Burden of Diarrhea Due to Enterotoxigenic <i>Escherichia coli</i> among Rural Egyptian Infants and Young Children. Journal of Clinical Microbiology, 2003, 41, 4862-4864.	3.9	78
35	BREAST FEEDING AND THE RISK OF SEVERE CHOLERA IN RURAL BANGLADESHI CHILDREN. American Journal of Epidemiology, 1990, 131, 400-411.	3.4	77
36	<i>Helicobacter pylori</i> induce neutrophil transendothelial migration: Role of the bacterial HP-NAP. FEMS Microbiology Letters, 2005, 249, 95-103.	1.8	76

#	ARTICLE	IF	CITATIONS
37	Refinement of a Human Challenge Model for Evaluation of Enterotoxigenic Escherichia coli Vaccines. Vaccine Journal, 2011, 18, 1719-1727.	3.1	76
38	Progress in enteric vaccine development. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 421-445.	2.4	72
39	The Major Subunit, CfaB, of Colonization Factor Antigen I from Enterotoxigenic Escherichia coli Is a Glycosphingolipid Binding Protein. Infection and Immunity, 2006, 74, 3488-3497.	2.2	70
40	HpaA Is Essential for Helicobacter pylori Colonization in Mice. Infection and Immunity, 2006, 74, 920-926.	2.2	70
41	Colonization factors among enterotoxigenic Escherichia coli isolates from children with moderate-to-severe diarrhea and from matched controls in the Global Enteric Multicenter Study (GEMS). PLoS Neglected Tropical Diseases, 2019, 13, e0007037.	3.0	68
42	Enterotoxigenic Escherichia coli with STh and STp Genotypes Is Associated with Diarrhea Both in Children in Areas of Endemicity and in Travelers. Journal of Clinical Microbiology, 2006, 44, 3872-3877.	3.9	65
43	Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatric Infectious Disease Journal, 2002, 21, 322-330.	2.0	64
44	Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine, 2004, 22, 984-990.	3.8	64
45	Impact of Rapid Urbanization on the Rates of Infection by Vibrio cholerae O1 and Enterotoxigenic Escherichia coli in Dhaka, Bangladesh. PLoS Neglected Tropical Diseases, 2011, 5, e999.	3.0	62
46	Natural Killer Cells and Helicobacter pylori Infection: Bacterial Antigens and Interleukin-12 Act Synergistically To Induce Gamma Interferon Production. Infection and Immunity, 2005, 73, 1482-1490.	2.2	61
47	Characterization of the Outer Membrane Protein Profile from Disease-Related Helicobacter pylori Isolates by Subcellular Fractionation and Nano-LC FT-ICR MS Analysis. Journal of Proteome Research, 2006, 5, 3197-3204.	3.7	61
48	Serologic Correlates of Protection against Enterotoxigenic Escherichia coli Diarrhea. Journal of Infectious Diseases, 2005, 191, 562-570.	4.0	60
49	Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses. Vaccine, 2007, 25, 2591-2598.	3.8	60
50	Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access. Vaccine, 2021, 39, 4266-4277.	3.8	60
51	Phenotypic Diversity of Enterotoxigenic Escherichia coli Strains from a Community-Based Study of Pediatric Diarrhea in Periurban Egypt. Journal of Clinical Microbiology, 1999, 37, 2974-2978.	3.9	60
52	Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children. Vaccine, 2000, 18, 2704-2712.	3.8	59
53	Increased Levels of Inflammatory Mediators in Children and Adults Infected with Vibrio cholerae O1 and O139. Vaccine Journal, 2002, 9, 221-229.	3.1	59
54	Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine, 2003, 21, 2394-2403.	3.8	57

#	ARTICLE	IF	CITATIONS
55	Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. <i>Vaccine</i> , 2009, 27, 1433-1439.	3.8	57
56	Reduced doses of oral killed enterotoxigenic <i>Escherichia coli</i> plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6–17 months of age: Dosing studies in different age groups. <i>Vaccine</i> , 2006, 24, 1726-1733.	3.8	55
57	Shifting prevalence of major diarrheal pathogens in patients seeking hospital care during floods in 1998, 2004, and 2007 in Dhaka, Bangladesh. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 708-14.	1.4	55
58	Epitope differences in toxin-coregulated pili produced by classical and El Tor <i>Vibrio cholerae</i> O1. <i>Microbial Pathogenesis</i> , 1991, 11, 179-188.	2.9	53
59	Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. <i>Vaccine</i> , 1993, 11, 1007-1012.	3.8	53
60	Enterotoxigenic <i>Escherichia coli</i> Isolated from Surface Water in Urban and Rural Areas of Bangladesh. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3582-3583.	3.9	52
61	Prospective Cohort Study of Enterotoxigenic <i>Escherichia coli</i> Infections in Argentinean Children. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2829-2833.	3.9	50
62	Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic <i>Escherichia coli</i> vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses. <i>Vaccine</i> , 2019, 37, 5645-5656.	3.8	48
63	Characterization of Enterotoxigenic <i>Escherichia coli</i> Strains in Patients with Travelers' Diarrhea Acquired in Guadalajara, Mexico, 1992–1997. <i>Journal of Infectious Diseases</i> , 2000, 181, 779-782.	4.0	46
64	Induction of Systemic Antifimbria and Antitoxin Antibody Responses in Egyptian Children and Adults by an Oral, Killed Enterotoxigenic <i>Escherichia coli</i> plus Cholera Toxin B Subunit Vaccine. <i>Infection and Immunity</i> , 2001, 69, 2853-2857.	2.2	46
65	Failure To Detect <i>Helicobacter pylori</i> DNA in Drinking and Environmental Water in Dhaka, Bangladesh, Using Highly Sensitive Real-Time PCR Assays. <i>Applied and Environmental Microbiology</i> , 2009, 75, 3039-3044.	3.1	46
66	Sulfatide Recognition by Colonization Factor Antigen CS6 from Enterotoxigenic <i>Escherichia coli</i> . <i>PLoS ONE</i> , 2009, 4, e4487.	2.5	45
67	Induction and Assessment of Immunity at Enteromucosal Surfaces in Humans: Implications for Vaccine Development. <i>Clinical Infectious Diseases</i> , 1993, 16, S106-S116.	5.8	44
68	Immunological memory after immunization with oral cholera B subunit-whole-cell vaccine in Swedish volunteers. <i>Vaccine</i> , 1994, 12, 1078-1082.	3.8	44
69	Shift in Phenotypic Characteristics of Enterotoxigenic <i>Escherichia coli</i> (ETEC) Isolated from Diarrheal Patients in Bangladesh. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3031.	3.0	43
70	Antitoxic Cholera Immunity in Mice: Influence of Antigen Deposition on Antitoxin-Containing Cells and Protective Immunity in Different Parts of the Intestine. <i>Infection and Immunity</i> , 1980, 28, 17-23.	2.2	43
71	Infection by <i>Helicobacter Pylori</i> in Bangladeshi Children From Birth to Two Years. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 79-85.	2.0	42
72	Enterotoxins, colonization factors, serotypes and antimicrobial resistance of enterotoxigenic <i>Escherichia coli</i> (ETEC) strains isolated from hospitalized children with diarrhea in Bolivia. <i>Brazilian Journal of Infectious Diseases</i> , 2011, 15, 132-137.	0.6	39

#	ARTICLE	IF	CITATIONS
73	Intestinal Immune Responses in Patients Infected with Enterotoxigenic <i>Escherichia coli</i> and in Vaccinees. <i>Infection and Immunity</i> , 1999, 67, 6234-6241.	2.2	39
74	Differences in Surface-Exposed Antigen Expression between <i>Helicobacter pylori</i> Strains Isolated from Duodenal Ulcer Patients and from Asymptomatic Subjects. <i>Journal of Clinical Microbiology</i> , 2000, 38, 3436-3441.	3.9	38
75	Children with the Le(a+b <sup>+</sup> ) Blood Group Have Increased Susceptibility to Diarrhea Caused by Enterotoxigenic <i>Escherichia coli</i> Expressing Colonization Factor I Group Fimbriae. <i>Infection and Immunity</i> , 2009, 77, 2059-2064.	2.2	37
76	From cholera to enterotoxigenic <i>Escherichia coli</i> (ETEC) vaccine development. <i>Indian Journal of Medical Research</i> , 2011, 133, 188-96.	1.0	37
77	Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines. <i>Vaccine</i> , 1990, 8, 469-472.	3.8	36
78	Dendritic cells express CCR7 and migrate in response to CCL19 (MIP-3 $\beta$ ) after exposure to <i>Helicobacter pylori</i> . <i>Microbes and Infection</i> , 2006, 8, 841-850.	1.9	36
79	Double-Blind, Randomized, Placebo Controlled Pilot Study Evaluating Efficacy and Reactogenicity of an Oral ETEC B-Subunit-Inactivated Whole Cell Vaccine against Travelers' Diarrhea (Preliminary) <i>Tj ETQq1 1 0.784314 rgB76/Overlo</i>	1.0	36
80	Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic <i>Escherichia coli</i> vaccine. <i>Vaccine</i> , 2016, 34, 3132-3140.	3.8	36
81	Identification of new heat-stable (STa) enterotoxin allele variants produced by human enterotoxigenic <i>Escherichia coli</i> (ETEC). <i>International Journal of Medical Microbiology</i> , 2016, 306, 586-594.	3.6	36
82	Cross-reactivity and avidity of antibody responses induced in humans by the oral inactivated multivalent enterotoxigenic <i>Escherichia coli</i> (ETEC) vaccine ETVAX. <i>Vaccine</i> , 2017, 35, 3966-3973.	3.8	36
83	<i>Campylobacter jejuni/coli</i> and Enterotoxigenic <i>Escherichia coli</i> (ETEC) in Faeces from Children and Adults in Tanzania. <i>Scandinavian Journal of Infectious Diseases</i> , 1995, 27, 589-593.	1.5	35
84	Expression of Colonization Factor CS5 of Enterotoxigenic <i>Escherichia coli</i> (ETEC) Is Enhanced In Vivo and by the Bile Component Na Glycocholate Hydrate. <i>PLoS ONE</i> , 2012, 7, e35827.	2.5	35
85	T and B cell responses to chimeric proteins containing heterologous T helper epitopes inserted at different positions. <i>Molecular Immunology</i> , 1992, 29, 1185-1190.	2.2	34
86	Breast Milk Reduces the Risk of Illness in Children of Mothers With Cholera. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 1163-1166.	2.0	34
87	Progress in vaccine development against <i>Helicobacter pylori</i> . <i>FEMS Immunology and Medical Microbiology</i> , 2007, 50, 146-156.	2.7	34
88	Different kinetics of circulating antibody-secreting cell responses after primary and booster oral immunizations: A tool for assessing immunological memory. <i>Vaccine</i> , 2013, 31, 3035-3038.	3.8	32
89	Construction of non-toxic <i>Escherichia coli</i> and <i>Vibrio cholerae</i> strains expressing high and immunogenic levels of enterotoxigenic <i>E. coli</i> colonization factor I fimbriae. <i>Vaccine</i> , 2008, 26, 743-752.	3.8	31
90	Dose-Dependent Circulating Immunoglobulin A Antibody-Secreting Cell and Serum Antibody Responses in Swedish Volunteers to an Oral Inactivated Enterotoxigenic <i>Escherichia coli</i> Vaccine. <i>Vaccine Journal</i> , 2001, 8, 424-428.	2.6	30

#	ARTICLE	IF	CITATIONS
91	The local and systemic T-cell response to <i>Helicobacter pylori</i> in gastric cancer patients is characterised by production of interleukin-10. <i>Clinical Immunology</i> , 2007, 125, 205-213.	3.2	30
92	Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent <i>V. cholerae</i> O1/O139 whole cell cholera vaccine: Comparison with other mucosal and systemic responses. <i>Vaccine</i> , 2009, 27, 1386-1392.	3.8	30
93	FUT2 non-secretor status is associated with altered susceptibility to symptomatic enterotoxigenic <i>Escherichia coli</i> infection in Bangladeshis. <i>Scientific Reports</i> , 2017, 7, 10649.	3.3	30
94	Strategies to overexpress enterotoxigenic <i>Escherichia coli</i> (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates. <i>Applied Microbiology and Biotechnology</i> , 2012, 93, 2291-2300.	3.6	29
95	Evaluation of immune responses to an oral typhoid vaccine, Ty21a, in children from 2 to 5 years of age in Bangladesh. <i>Vaccine</i> , 2014, 32, 1055-1060.	3.8	29
96	Estimation of Symptomatic and Asymptomatic <i>Salmonella</i> Infections. <i>Scandinavian Journal of Infectious Diseases</i> , 1990, 22, 451-455.	1.5	28
97	Prevalence, seasonality and severity of disease caused by pathogenic <i>Escherichia coli</i> in children with diarrhoea in Bolivia. <i>Journal of Medical Microbiology</i> , 2013, 62, 1697-1706.	1.8	28
98	Monoclonal antibodies against fimbrial subunits of colonization factor antigen I (CFA/I) inhibit binding to human enterocytes and protect against enterotoxigenic <i>Escherichia coli</i> expressing heterologous colonization factors. <i>Microbial Pathogenesis</i> , 1996, 21, 35-45.	2.9	27
99	Safety and Immunogenicity of Two Different Lots of the Oral, Killed Enterotoxigenic <i>Escherichia coli</i> -Cholera Toxin B Subunit Vaccine in Israeli Young Adults. <i>Infection and Immunity</i> , 2000, 68, 4492-4497.	2.2	27
100	Flow cytometric analysis of the localization of <i>Helicobacter pylori</i> antigens during different growth phases. <i>FEMS Immunology and Medical Microbiology</i> , 2001, 30, 173-179.	2.7	27
101	Homologous and Cross-Reactive Immune Responses to Enterotoxigenic <i>Escherichia coli</i> Colonization Factors in Bangladeshi Children. <i>Infection and Immunity</i> , 2006, 74, 4512-4518.	2.2	27
102	Mucosal and Systemic Immune Responses in Patients with Diarrhea Due to CS6-Expressing Enterotoxigenic <i>Escherichia coli</i> . <i>Infection and Immunity</i> , 2007, 75, 2269-2274.	2.2	27
103	Construction of a non-toxigenic <i>Escherichia coli</i> oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice. <i>Vaccine</i> , 2011, 29, 8863-8869.	3.8	27
104	Gastric expression of IL-17A and IFN $\gamma$ in <i>Helicobacter pylori</i> infected individuals is related to symptoms. <i>Cytokine</i> , 2017, 99, 30-34.	3.2	27
105	Enterotoxin-producing bacteria isolated from Swedish travellers with diarrhoea. <i>Scandinavian Journal of Infectious Diseases</i> , 1991, 23, 473-479.	1.5	26
106	Colonization factor antigens (CFAs) of enterotoxigenic <i>Escherichia coli</i> can prime and boost immune responses against heterologous CFAs. <i>Microbial Pathogenesis</i> , 1994, 16, 131-139.	2.9	25
107	Binding of enterotoxigenic <i>Escherichia coli</i> expressing different colonization factors to tissue-cultured Caco-2 cells and to isolated human enterocytes. <i>Microbial Pathogenesis</i> , 1996, 21, 139-147.	2.9	25
108	In vivo expression of the heat stable ( <i>estA</i> ) and heat labile ( <i>eltB</i> ) toxin genes of enterotoxigenic <i>Escherichia coli</i> (ETEC). <i>Microbes and Infection</i> , 2006, 8, 2797-2802.	1.9	25

#	ARTICLE	IF	CITATIONS
109	Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children. <i>Vaccine</i> , 2013, 31, 647-652.	3.8	25
110	Molecular Characterization of Enterotoxigenic <i>Escherichia coli</i> Isolates Recovered from Children with Diarrhea during a 4-Year Period (2007 to 2010) in Bolivia. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1219-1225.	3.9	25
111	Antigen-Specific Memory B-cell Responses to Enterotoxigenic <i>Escherichia coli</i> Infection in Bangladeshi Adults. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2822.	3.0	25
112	Experimental Studies on Cholera Immunization. <i>International Archives of Allergy and Immunology</i> , 1975, 49, 434-452.	2.1	24
113	Immunological cross-reactivity between <i>Escherichia coli</i> heat-labile enterotoxin and cholera toxin A and B subunits. <i>Current Microbiology</i> , 1979, 2, 55-58.	2.2	24
114	Enterotoxigenic <i>Escherichia coli</i> colonization factor types collected from 1997 to 2001 in US military personnel during operation Bright Star in northern Egypt. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 55, 9-12.	1.8	24
115	Role of different genes in the CS6 operon for surface expression of Enterotoxigenic <i>Escherichia coli</i> colonization factor CS6. <i>Vaccine</i> , 2008, 26, 5373-5380.	3.8	24
116	Decreased IgA antibody production in the stomach of gastric adenocarcinoma patients. <i>Clinical Immunology</i> , 2009, 131, 463-471.	3.2	24
117	Identification and characterization of the novel colonization factor CS30 based on whole genome sequencing in enterotoxigenic <i>Escherichia coli</i> (ETEC). <i>Scientific Reports</i> , 2017, 7, 12514.	3.3	24
118	A recombinant <i>Escherichia coli</i> heat-stable enterotoxin (STa) fusion protein eliciting anti-STa neutralizing antibodies. <i>FEMS Microbiology Letters</i> , 1991, 82, 271-278.	1.8	23
119	Binding of enterotoxigenic <i>Escherichia coli</i> to isolated enterocytes and intestinal mucus. <i>Microbial Pathogenesis</i> , 1997, 23, 335-346.	2.9	23
120	B cells pulsed with <i>Helicobacter pylori</i> antigen efficiently activate memory CD8 <sup>+</sup> T cells from <i>H. pylori</i> -infected individuals. <i>Clinical Immunology</i> , 2006, 118, 284-291.	3.2	23
121	FOXP3 <sup>+</sup> expressing CD4 <sup>+</sup> T <sub>H</sub> cell Numbers Increase in Areas of Duodenal Gastric Metaplasia and are Associated to CD4 <sup>+</sup> T <sub>H</sub> cell Aggregates in the Duodenum of <i>Helicobacter pylori</i> -infected Duodenal Ulcer Patients. <i>Helicobacter</i> , 2009, 14, 192-201.	3.5	23
122	Impaired IFN- $\gamma$ production after stimulation with bacterial components by natural killer cells from gastric cancer patients. <i>Experimental Cell Research</i> , 2011, 317, 849-858.	2.6	23
123	Allele Variants of Enterotoxigenic <i>Escherichia coli</i> Heat-Labile Toxin Are Globally Transmitted and Associated with Colonization Factors. <i>Journal of Bacteriology</i> , 2015, 197, 392-403.	2.2	23
124	Synthesis on nontoxic, antibody-binding <i>Escherichia coli</i> heat-stable enterotoxin (STa) peptides. <i>FEMS Microbiology Letters</i> , 1988, 55, 23-28.	1.8	22
125	Expression of virulence factors by classical and El Tor <i>Vibrio cholerae</i> in vivo and in vitro. <i>FEMS Microbiology Letters</i> , 1990, 74, 221-228.	1.8	22
126	Enhanced immunogenicity of recombinant peptide fusions containing multiple copies of a heterologous T helper epitope. <i>European Journal of Immunology</i> , 1990, 20, 1541-1545.	2.9	22



#	ARTICLE	IF	CITATIONS
127	Reduction in Capsular Content and Enhanced Bacterial Susceptibility to Serum Killing of <i>Vibrio cholerae</i> O139 Associated with the 2002 Cholera Epidemic in Bangladesh. <i>Infection and Immunity</i> , 2005, 73, 6577-6583.	2.2	22
128	Etiology of Travelers' Diarrhea on a Caribbean Island. <i>Journal of Travel Medicine</i> , 2000, 7, 15-18.	3.0	22
129	Over-expression of major colonization factors of enterotoxigenic <i>Escherichia coli</i> , alone or together, on non-toxigenic <i>E. coli</i> bacteria. <i>Vaccine</i> , 2010, 28, 6977-6984.	3.8	22
130	Antigenic variation within the subunit protein of members of the colonization factor antigen I group of fimbrial proteins in human enterotoxigenic <i>Escherichia coli</i> . <i>International Journal of Medical Microbiology</i> , 2002, 292, 43-50.	3.6	21
131	Immune Responses to <i>Helicobacter pylori</i> Infection in Bangladeshi Children during Their First Two Years of Life and the Association between Maternal Antibodies and Onset of Infection. <i>Journal of Infectious Diseases</i> , 2010, 202, 1676-1684.	4.0	21
132	Development of a new method for the determination of immune responses in the human stomach. <i>Journal of Immunological Methods</i> , 2000, 234, 51-59.	1.4	20
133	Presence of High Numbers of Transcriptionally Active <i>Helicobacter pylori</i> in Vomitus from Bangladeshi Patients Suffering from Acute Gastroenteritis. <i>Helicobacter</i> , 2009, 14, 237-247.	3.5	20
134	Concomitant Enterotoxigenic <i>Escherichia coli</i> Infection Induces Increased Immune Responses to <i>Vibrio cholerae</i> O1 Antigens in Patients with Cholera in Bangladesh. <i>Infection and Immunity</i> , 2010, 78, 2117-2124.	2.2	20
135	Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country. <i>Vaccine</i> , 2017, 35, 321-328.	3.8	20
136	Mechanisms involved in <i>Helicobacter pylori</i> induced duodenal ulcer disease: an overview. <i>World Journal of Gastroenterology</i> , 2000, 6, 619.	3.3	20
137	GM1 ELISA method for demonstration of <i>Escherichia coli</i> heat-stable enterotoxin. <i>FEMS Microbiology Letters</i> , 1985, 30, 1-6.	1.8	19
138	Surface expression of <i>Helicobacter pylori</i> HpaA adhesion antigen on <i>Vibrio cholerae</i> , enhanced by co-expressed enterotoxigenic <i>Escherichia coli</i> fimbrial antigens. <i>Microbial Pathogenesis</i> , 2017, 105, 177-184.	2.9	18
139	Different <i>Helicobacter pylori</i> Strains Colonize the Antral and Duodenal Mucosa of Duodenal Ulcer Patients. <i>Helicobacter</i> , 2000, 5, 69-78.	3.5	17
140	Prospects for a mucosally-administered vaccine against <i>Helicobacter pylori</i> . <i>Vaccine</i> , 2003, 21, 347-353.	3.8	17
141	T- and B-Cell Immune Responses of Patients Who Had Undergone Colectomies to Oral Administration of <i>Salmonella enterica</i> Serovar Typhi Ty21a Vaccine. <i>Vaccine Journal</i> , 2003, 10, 426-430.	3.1	17
142	Mutations in the periplasmic chaperone leading to loss of surface expression of the colonization factor CS6 in enterotoxigenic <i>Escherichia coli</i> (ETEC) clinical isolates. <i>Microbial Pathogenesis</i> , 2008, 44, 246-254.	2.9	17
143	CD8 <sup>+</sup> Natural Killer Cells Are Greatly Enriched in the Human Gastrointestinal Tract and Have the Capacity to Respond to Bacteria. <i>Journal of Innate Immunity</i> , 2010, 2, 294-302.	3.8	17
144	Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants. <i>Vaccine</i> , 2022, 40, 380-389.	3.8	17

#	ARTICLE	IF	CITATIONS
145	Mechanism of spontaneous loss of heat-stable toxin (STa) production in enterotoxigenic <i>Escherichia coli</i> . <i>Apmis</i> , 1989, 97, 436-440.	2.0	16
146	Determinants of Responses to Oral Vaccines in Developing Countries. <i>Annales Nestle</i> , 2008, 66, 71-79.	0.1	16
147	Pathogenicity and Phenotypic Characterization of Enterotoxigenic <i>Escherichia coli</i> Isolates from a Birth Cohort of Children in Rural Egypt. <i>Journal of Clinical Microbiology</i> , 2014, 52, 587-591.	3.9	16
148	Implications of enterotoxigenic <i>Escherichia coli</i> genomics for vaccine development. <i>Expert Review of Vaccines</i> , 2015, 14, 551-560.	4.4	16
149	Clinical aspects of heat-labile and heat-stable toxin-producing enterotoxigenic <i>Escherichia coli</i> : A prospective study among Finnish travellers. <i>Travel Medicine and Infectious Disease</i> , 2020, 38, 101855.	3.0	16
150	Oral Vaccines against Cholera and Enterotoxigenic <i>Escherichia coli</i> Diarrhea. , 1996, , 241-253.		16
151	Isolation of <i>Escherichia coli</i> heat-labile enterotoxin by affinity chromatography: Characterization of subunits. <i>Current Microbiology</i> , 1980, 3, 339-344.	2.2	15
152	Induction of colonization factor antigen I (CFA/I) and coli surface antigen 4 (CS4) of enterotoxigenic <i>Escherichia coli</i> : relevance for vaccine production. <i>Vaccine</i> , 1993, 11, 221-226.	3.8	15
153	Local and systemic immune responses in humans against <i>Helicobacter pylori</i> antigens from homologous and heterologous strains. <i>Microbial Pathogenesis</i> , 1997, 23, 285-296.	2.9	15
154	Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and <i>Shigella</i> infections, and their potential to serve as correlates of protection in vaccine development. <i>Vaccine</i> , 2019, 37, 4787-4793.	3.8	15
155	Mucosal Immune Responses Against an Oral Enterotoxigenic <i>Escherichia coli</i> Vaccine Evaluated in Clinical Trials. <i>Journal of Infectious Diseases</i> , 2021, 224, S821-S828.	4.0	15
156	Immunological response to <i>Vibrio cholerae</i> O1 infection and an oral cholera vaccine among Peruvians. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1995, 89, 542-545.	1.8	14
157	<i>Helicobacter pylori</i> inflammation, immunity and vaccines. <i>Helicobacter</i> , 2003, 8, 31-35.	3.5	14
158	Construction and expression of immunogenic hybrid enterotoxigenic <i>Escherichia coli</i> CFA/I and CS2 colonization fimbriae for use in vaccines. <i>Applied Microbiology and Biotechnology</i> , 2010, 87, 1355-1365.	3.6	14
159	Presence of <i>cfaD</i> -homologous sequences and expression of coli surface antigen 4 on enterotoxigenic <i>Escherichia coli</i> ; relevance for diagnostic procedures. <i>Microbial Pathogenesis</i> , 1991, 11, 297-304.	2.9	13
160	The expression of the <i>Helicobacter pylori</i> genes <i>ureA</i> and <i>napis</i> higher in vivo than in vitro as measured by quantitative competitive reverse transcriptase-PCR. <i>FEMS Immunology and Medical Microbiology</i> , 2002, 32, 219-226.	2.7	13
161	Detection of Antibodies to Toxin-Coregulated Pili in Sera from Cholera Patients. <i>Infection and Immunity</i> , 2004, 72, 1824-1827.	2.2	13
162	Enterotoxigenic <i>Escherichia coli</i> Multilocus Sequence Types in Guatemala and Mexico. <i>Emerging Infectious Diseases</i> , 2010, 16, 143-145.	4.3	13

#	ARTICLE	IF	CITATIONS
163	Immune Responses Against <i>Helicobacter pylori</i> in Gastric Cancer Patients and in Risk Groups for Gastric Cancer. <i>Helicobacter</i> , 2013, 18, 73-82.	3.5	13
164	Enterotoxins, colonization factors, serotypes and antimicrobial resistance of enterotoxigenic <i>Escherichia coli</i> (ETEC) strains isolated from hospitalized children with diarrhea in Bolivia. <i>Brazilian Journal of Infectious Diseases</i> , 2011, 15, 132-137.	0.6	13
165	Priming and expression of immune responses in the gastric mucosa. <i>Microbes and Infection</i> , 2003, 5, 731-739.	1.9	12
166	Long-read-sequenced reference genomes of the seven major lineages of enterotoxigenic <i>Escherichia coli</i> (ETEC) circulating in modern time. <i>Scientific Reports</i> , 2021, 11, 9256.	3.3	12
167	Immunity to <i>Vibrio cholerae</i> Infection. , 0, , 257-271.		12
168	Immune Responses in Ileostomy Fluid and Serum after Oral Cholera Vaccination of Patients Colectomized because of Ulcerative Colitis. <i>Infection and Immunity</i> , 1998, 66, 3995-3999.	2.2	12
169	Antibody Responses in Humans against Coli Surface Antigen 6 of Enterotoxigenic <i>Escherichia coli</i> . <i>Infection and Immunity</i> , 1998, 66, 4507-4510.	2.2	12
170	A comparison of seasonal variations in rotavirus antibodies in the breast milk of Swedish and Bangladeshi mothers. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2015, 104, 247-251.	1.5	11
171	The Nature of Protective Immunity in Cholera1. , 1980, , 171-184.		10
172	Identification of asialo GM1 as a binding structure for <i>Escherichia coli</i> colonization factor antigens. <i>FEMS Microbiology Letters</i> , 1990, 72, 289-292.	1.8	10
173	Comparison of mucosal B- and T-cell responses in <i>Helicobacter pylori</i> -infected subjects in a developing and a developed country. <i>FEMS Immunology and Medical Microbiology</i> , 2008, 54, 70-79.	2.7	10
174	Enumeration of Gut-Homing $\gamma\delta$ 7-Positive, Pathogen-Specific Antibody-Secreting Cells in Whole Blood from Enterotoxigenic <i>Escherichia coli</i> - and <i>Vibrio cholerae</i> -Infected Patients, Determined Using an Enzyme-Linked Immunosorbent Spot Assay Technique. <i>Vaccine Journal</i> , 2016, 23, 27-36.	3.1	10
175	Stability of the Encoding Plasmids and Surface Expression of CS6 Differs in Enterotoxigenic <i>Escherichia coli</i> (ETEC) Encoding Different Heat-Stable (ST) Enterotoxins (STh and STp). <i>PLoS ONE</i> , 2016, 11, e0152899.	2.5	10
176	COLONIZATION, DIARRHOEA AND PROTECTIVE IMMUNOGENICITY OF A CFA/II DEFICIENT, ENTEROTOXIN-PRODUCING <i>ESCHERICHIA COLI</i> MUTANT IN A NON-LIGATED INTESTINE EXPERIMENTAL MODEL. <i>Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section B, Microbiology</i> , 1987, 95B, 123-130.	0.1	9
177	Induction and Distribution of Intestinal Immune Responses after Administration of Recombinant Cholera Toxin B Subunit in the Ileal Pouches of Colectomized Patients. <i>Infection and Immunity</i> , 2001, 69, 3466-3471.	2.2	8
178	Detection of the CS20 colonization factor antigen in diffuse-adhering <i>Escherichia coli</i> strains. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 60, 186-189.	2.7	8
179	A Prospective Study of Serum Antibody Responses to Enterotoxinogenic <i>Escherichia coli</i> in Swedish Travellers. <i>Scandinavian Journal of Infectious Diseases</i> , 1988, 20, 69-75.	1.5	7
180	Glyco-engineered cell line and computational docking studies reveals enterotoxigenic <i>Escherichia coli</i> CFA/II fimbriae bind to Lewis a glycans. <i>Scientific Reports</i> , 2018, 8, 11250.	3.3	7

#	ARTICLE	IF	CITATIONS
181	Monoclonal Antibodies and Immunodetection Methods for <i>Vibrio cholerae</i> and <i>Escherichia coli</i> Enterotoxins. , 1986, , 77-97.		7
182	Mucosal Immunity to Bacteria. , 2005, , 783-797.		7
183	Déterminants des réponses aux vaccins oraux dans les pays en développement. Annales Nestle [Ed Francaise], 2008, 66, 71-80.	0.0	6
184	Booster vaccination with a fractional dose of an oral cholera vaccine induces comparable vaccine-specific antibody avidity as a full dose: A randomised clinical trial. Vaccine, 2020, 38, 655-662.	3.8	6
185	A Systems Biology Approach Identifies B Cell Maturation Antigen (BCMA) as a Biomarker Reflecting Oral Vaccine Induced IgA Antibody Responses in Humans. Frontiers in Immunology, 2021, 12, 647873.	4.8	6
186	Production and characterization of monoclonal antibodies to <i>Vibrio cholerae</i> soluble haemagglutinin. Apmis, 1991, 99, 249-256.	2.0	5
187	<i>Helicobacter pylori</i> Infection of the Gastric Mucosa. , 2015, , 985-1001.		4
188	A Radial Diffusion Agar Plaque Technique for Estimation of the Avidity of Bactericidal Antibodies against <i>Vibrio cholerae</i> . Scandinavian Journal of Immunology, 1972, 1, 345-350.	2.7	3
189	Serum Antibody Responses to Bacterial Enteropathogens in Swedish Travellers to South-East Asia. Scandinavian Journal of Infectious Diseases, 1990, 22, 699-704.	1.5	3
190	Enzyme-linked immunosorbent assay for determination of antibodies to <i>Vibrio cholerae</i> toxin coregulated pili. Apmis, 1992, 100, 1027-1032.	2.0	3
191	Antibodies to endotoxin from <i>Vibrio cholerae</i> measured by bactericidal and indirect hemagglutination tests. Differences in immunoglobulin classes and specificity. Journal of Immunological Methods, 1972, 1, 329-340.	1.4	2
192	Antibodies against <i>Helicobacter pylori</i> in feces and saliva before and after eradication therapy. Clinical Microbiology and Infection, 1998, 4, 634-643.	6.0	2
193	Oral Vaccines for Enterotoxigenic <i>Escherichia coli</i> . , 2020, , 563-578.		2
194	Expression of virulence factors by classical and El Tor <i>Vibrio cholerae</i> in vivo and in vitro. FEMS Microbiology Ecology, 1990, 7, 221-228.	2.7	1
195	Expression of virulence factors by classical and El Tor <i>Vibrio cholerae</i> in vivo and in vitro. FEMS Microbiology Letters, 1990, 74, 221-228.	1.8	1
196	Flow cytometric analysis of the localization of <i>Helicobacter pylori</i> antigens during different growth phases. FEMS Immunology and Medical Microbiology, 2001, 30, 173-179.	2.7	1
197	Vaccine Development for the Control of Cholera and Related Toxin-induced Diarrhoeal Diseases. Novartis Foundation Symposium, 1985, 112, 242-270.	1.1	1
198	Mucosal Immunity in the Gastrointestinal Tract in Relation to ETEC Vaccine Development. Progress in Vaccinology, 1989, , 181-196.	0.7	1

#	ARTICLE	IF	CITATIONS
199	Cholera and the Immune Response. <i>Chemical Immunology and Allergy</i> , 1983, 33, 106-119.	1.7	0
200	Determinantes de las respuestas a vacunas orales en países en vías de desarrollo. <i>Annales Nestlé</i> (Ed) Tj ETQq0,0 rgBT /Overlock 1	0.1	0
201	Response on letter by Arya et al.: "Evaluation of immune responses to an oral typhoid vaccine, Ty21a, in children from 2 to 5 years of age in Bangladesh." <i>Vaccine</i> , 2014, 32, 4014.	3.8	0
202	Assessing antigen specific HLA-DR+ antibody secreting cell (DR+ASC) responses in whole blood in enteric infections using an ELISPOT technique. <i>Microbes and Infection</i> , 2018, 20, 122-129.	1.9	0
203	Engineered bacterial toxin vaccines and adjuvants. , 2006, , 1008-1018.		0
204	Oral B Subunit-Whole Cell Vaccine Against Cholera: From Basic Research to Successful Field Trial. <i>Progress in Vaccinology</i> , 1989, , 119-130.	0.7	0
205	Mucosal Immune Responses Against Enterotoxigenic <i>Escherichia coli</i> [ETEC] in Humans. , 2008, , 153-171.		0